Regulonix, a US-based biotech spinout from University of Arizona (UA), raised $2m in a seed round on Tuesday led by UAVenture Capital Fund (UAVC), a VC firm focused on commercialising research from the institution.
Local angel investor group Desert Angels also contributed to the round. UAVC had disclosed its investment in Regulonix last month, though no further details were revealed at the time.
Regulonix is working on non-opioid drugs to treat chronic pain. The spinout’s compounds have proven non-addictive…
